Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Knight Therapeutics

Biotech & Life Sciences · Westmount, Canada · Founded 1995 · IPO 2014 Thoroughbred

Specialty pharmaceutical company focused on acquiring or in-licensing

Valuation
$526M
Market cap · May/2026
Revenue
$330M
Latest reported FY
EBITDA
$55M
Latest reported FY

Global footprint

Where Knight Therapeutics has talent and traffic

Workforce by country
14 countries with
team presence
🇨🇦 Canada24.6%
🇦🇷 Argentina18.8%
🇧🇷 Brazil17%
🇨🇴 Colombia15.6%
🇺🇾 Uruguay8.9%
Top 5 of 14 shown

Capital deployed

Knight Therapeutics's 4 investments and acquisitions.

Every disclosed deal where Knight Therapeutics appeared as a backer or acquirer, 2015–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Knight Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Knight Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Knight Therapeutics

        An AI-synthesized read of the highest-engagement posts about Knight Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Knight Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.